{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:03:07Z","timestamp":1790103787003,"version":"4.0.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1681\/asn.2014020212","type":"journal-article","created":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T23:23:05Z","timestamp":1406244185000},"page":"493-503","source":"Crossref","is-referenced-by-count":173,"title":["Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis"],"prefix":"10.1681","volume":"26","author":[{"given":"Julia B.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Sika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Koury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peale","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick C.","family":"Whittier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Linfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude M.","family":"Galphin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji P.","family":"Athreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Kaldun Kaldun","family":"Nossuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Zeig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotagal S.","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Olivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie P.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20230208","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0272-6386(12)80446-X","article-title":"Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease.","volume":"19","author":"Delmez","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"R2-28-20230208","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1681\/ASN.2008020141","article-title":"Serum phosphorus levels associate with coronary atherosclerosis in young adults.","volume":"20","author":"Foley","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R4-28-20230208","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1053\/j.ajkd.2012.11.041","article-title":"Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: A short-term randomized trial.","volume":"61","author":"Dwyer","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R5-28-20230208","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1681\/ASN.V1061274","article-title":"New phosphate binding agents: Ferric compounds.","volume":"10","author":"Hsu","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R8-28-20230208","doi-asserted-by":"crossref","first-page":"c25","DOI":"10.1159\/000341922","article-title":"The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.","volume":"121","author":"Sinsakul","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"R9-28-20230208","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1542-4758.2012.00711.x","article-title":"Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.","volume":"17","author":"Umanath","year":"2013","journal-title":"Hemodial Int"},{"key":"R10-28-20230208","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/17.2.265","article-title":"An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: Ferric citrate.","volume":"17","author":"Yang","year":"2002","journal-title":"Nephrol Dial Trasplant"},{"key":"R11-28-20230208","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000344008","article-title":"Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: Results of a randomized, double-blind, placebo-controlled trial.","volume":"36","author":"Yokoyama","year":"2012","journal-title":"Am J Nephrol"},{"key":"R12-28-20230208","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000083712","article-title":"Accumulation of metals and minerals from phosphate binders.","volume":"23","author":"Molony","year":"2005","journal-title":"Blood Purif"},{"key":"R13-28-20230208","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CNP65191","article-title":"Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients.","volume":"65","author":"Finn","year":"2006","journal-title":"Clin Nephrol"},{"key":"R17-28-20230208","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.ndt.a091722","article-title":"Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralisation.","volume":"3","author":"Moriniere","year":"1988","journal-title":"Nephrol Dial Trasplant"},{"key":"R19-28-20230208","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","article-title":"Oral phosphate binders in patients with kidney failure.","volume":"362","author":"Tonelli","year":"2010","journal-title":"N Engl J Med"},{"key":"R20-28-20230208","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1067\/mlc.2000.106807","article-title":"Effects of erythropoietin therapy on iron absorption in chronic renal failure.","volume":"135","author":"Skikne","year":"2000","journal-title":"J Lab Clin Med"},{"key":"R21-28-20230208","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000074931","article-title":"Iron requirements in hemodialysis.","volume":"22","author":"Sargent","year":"2004","journal-title":"Blood Purif"},{"key":"R22-28-20230208","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.ackd.2008.12.008","article-title":"Intravenous iron versus erythropoiesis-stimulating agents: Friends or foes in treating chronic kidney disease anemia?","volume":"16","author":"Kalantar-Zadeh","year":"2009","journal-title":"Adv Chronic Kidney Dis"},{"key":"R23-28-20230208","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrneph.2010.139","article-title":"Iron supplementation to treat anemia in patients with chronic kidney disease.","volume":"6","author":"Besarab","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"R24-28-20230208","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000045053","article-title":"Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study.","volume":"79","author":"Fudin","year":"1998","journal-title":"Nephron"},{"key":"R25-28-20230208","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/ki.1996.487","article-title":"A randomized controlled study of iron supplementation in patients treated with erythropoietin.","volume":"50","author":"Macdougall","year":"1996","journal-title":"Kidney Int"},{"key":"R26-28-20230208","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2012.10.002","article-title":"The DOPPS practice monitor for US dialysis care: Trends through December 2011.","volume":"61","author":"Fuller","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R27-28-20230208","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2215\/CJN.01070308","article-title":"Combined high serum ferritin and low iron saturation in hemodialysis patients: The role of inflammation.","volume":"3","author":"Rambod","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R28-28-20230208","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1681\/ASN.2007050606","article-title":"Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.","volume":"19","author":"Kapoian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R29-28-20230208","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients\u2019 Response to IV Iron with Elevated Ferritin (DRIVE) Study.","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R33-28-20230208","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1004967","article-title":"Iron overload in human disease.","volume":"366","author":"Fleming","year":"2012","journal-title":"N Engl J Med"},{"key":"R34-28-20230208","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/sim.1526","article-title":"Gatekeeping strategies for clinical trials that do not require all primary effects to be significant.","volume":"22","author":"Dmitrienko","year":"2003","journal-title":"Stat Med"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201502000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:33:25Z","timestamp":1786131205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201502000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2014020212","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}